Syra Health (SYRA) filed its Q3 2025 10‑Q, showing a smaller loss alongside a shift in revenue mix and a going concern warning. For the nine months ended September 30, 2025, net revenues were $5,491,944 versus $5,975,357 a year ago, as Healthcare Workforce declined and Population Health grew. Gross profit was $1,896,592 with a gross margin near 35%, up from roughly 22% last year, driven by mix toward higher‑margin project work.
Operating loss was $768,663 and net loss was $761,763, improving from $3,254,841 last year. Cash and cash equivalents were $1,976,545 as of September 30, 2025, with working capital of $2,156,762. The company disclosed substantial doubt about its ability to continue as a going concern and may need additional capital. Customer concentration remained high; Indiana FSSA accounted for approximately 37% of year‑to‑date revenue.
Corporate updates noted an April 11, 2025 voluntary delisting from Nasdaq to OTC QB and leadership changes in June, including appointment of an interim CEO. Class A shares outstanding were 11,339,169 as of November 11, 2025.
Syra Health Corp. filed an 8-K announcing it furnished its third-quarter 2025 results press release. The company reported that a press release covering the quarter ended September 30, 2025 is attached as Exhibit 99.1.
The company stated the information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and will not be incorporated by reference into other filings unless specifically referenced. The exhibit also includes forward-looking statements subject to cautionary language.
Syra Health Corp proxy excerpts show board composition, director changes, equity holdings and compensation details. The company has an insider trading policy for employees, officers, directors, consultants and related parties. Several directors and executives appear in compensation tables showing 2023 and 2024 total compensation in the low hundreds of thousands, with amounts such as $319,629, $200,730 and $171,291 reported for specific individuals. The disclosure lists equity awards and outstanding option counts for directors and significant holders, and notes audit-related fees of $17,000 and total fees of $92,000 and $114,755. The filing also records personnel changes: Sandeep Allam was reported deceased on January 15, 2025, Andrew Dahlem resigned the board on April 25, 2025, and Deepika Vuppalanchi resigned on July 28, 2025. The company states it does not have a written policy governing timing of option grants around material nonpublic information.